Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Chief Legal Officer and GC | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,889 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 37,500 · Balance 142,889 F1: Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 120,963 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Sale · Disposed 21,926 · Balance 120,963 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 107,089 |
Reported balance
After 2026-09-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-15 · Sale · Disposed 13,874 · Balance 107,089 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 105,689 |
Reported balance
After 2026-09-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-15 · Sale · Disposed 1,400 · Balance 105,689 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5: The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 105,389 |
Reported balance
After 2026-09-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-15 · Sale · Disposed 300 · Balance 105,389 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.46 · Expires 2030-01-31 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 37,500 · Balance 0 F6: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3: The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2020 Filed Sep 24, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,500 | $18.48 | $27,720.00 |
DisclosureSEC source: 0001209191-20-051735 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 01:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,500 | $18.59 | $27,885.00 |
DisclosureSEC source: 0001209191-20-051613 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,931 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051613 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,431 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 527 | $16.98 | $8,950.73 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 525 | $17.16 | $9,009.00 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,958 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 525 | $14.95 | $7,848.75 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,483 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 23:44 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,500 | $15.02 | $52,570.00 |
DisclosureSEC source: 0001209191-20-018648 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,008 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:07 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017540 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,508 F1 · kind: On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 7,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005903 · doc4.xml · derivative · entry 4 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005903 · doc4.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 55,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001209191-20-005903 · doc4.xml · derivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005903 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,008 Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 02:01 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 750 | $15.14 | $11,355.00 |
DisclosureSEC source: 0001209191-20-002635 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,008 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 02:01 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 750 | $13.94 | $10,455.00 |
DisclosureSEC source: 0001209191-20-002635 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,758 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 15, 2019 Filed May 17, 2019 01:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 525 | $17.71 | $9,297.75 |
DisclosureSEC source: 0001209191-19-030658 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,508 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.70 to $17.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 14, 2019 Filed May 17, 2019 01:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 525 | $17.75 | $9,318.75 |
DisclosureSEC source: 0001209191-19-030658 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,033 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6598 to $17.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · derivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,558 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:50 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 884 | $21.50 | $19,006.00 |
DisclosureSEC source: 0001209191-19-009927 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,558 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:50 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 885 | $21.38 | $18,921.30 |
DisclosureSEC source: 0001209191-19-009927 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,442 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 00:43 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 750 | $23.82 | $17,865.00 |
DisclosureSEC source: 0001209191-19-003163 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,327 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 00:43 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 750 | $24.09 | $18,067.50 |
DisclosureSEC source: 0001209191-19-003163 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 100 | $24.81 | $2,480.50 |
DisclosureSEC source: 0001209191-18-059066 · doc4.xml · nonDerivative · entry 5 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,827 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 100 | $24.77 | $2,477.00 |
DisclosureSEC source: 0001209191-18-059066 · doc4.xml · nonDerivative · entry 4 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,927 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,300 | $24.29 | $55,858.49 |
DisclosureSEC source: 0001209191-18-059066 · doc4.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,027 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.76 to $24.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 300 | $24.57 | $7,371.00 |
DisclosureSEC source: 0001209191-18-059066 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,327 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,200 | $23.62 | $51,958.94 |
DisclosureSEC source: 0001209191-18-059066 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,627 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $23.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 09, 2018 Filed Nov 15, 2018 01:45 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058650 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,827 F1 · kind: On January 4, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030058 · doc4.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 42,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030058 · doc4.xml · derivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030058 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,827 Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:42 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 1,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009403 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,827 Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 00:58 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 942 | $24.04 | $22,645.68 |
DisclosureSEC source: 0001209191-18-002805 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,058 F1 · kind: Shares were sold pursuant to a sell to cover election previously made, and confirmed by the Reporting Person during an open trading window, to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:22 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-17-002649 · doc4.xml · derivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option shall vest and become exercisable on the first anniversary of the date of grant, and the remaining shares shall vest and become exercisable in twelve equal quarterly installments thereafter. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:22 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002649 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.